Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Idera's IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket

Published 06/23/2017, 09:16 AM
© Reuters.  Idera's IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket
ACGN
-
  • Idera Pharmaceuticals (NASDAQ:IDRA) is up 5% premarket on average volume on the heels of its announcement that the FDA has designated Phase 2-stage IMO-2125 an Orphan Drug for the treatment of Stages IIB to IV melanoma.
  • IMO-2125 is an agonist of endosomal Toll-like receptor (TLR) 9, a cell surface protein that plays a key role in pathogen recognition and innate immunity.
  • Among the benefits of Orphan Drug status in the U.S. is an additional seven-year period of market exclusivity for the indication, if approved.
  • Now read: An Upcoming Conversation With An Expert: Understanding Osteoporosis And Treatment With TYMLOS, Plus ACTIVExtend Results


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.